Enanta Pharmaceuticals (ENTA) Current Assets (2012 - 2026)

Enanta Pharmaceuticals has reported Current Assets for 15 years, with the latest figure at $178.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 26.54% year-over-year to $178.4 million; the trailing twelve-month figure through Mar 2026 stood at $178.4 million (down 26.54% YoY), and the FY2025 full-year result was $204.3 million, down 31.85% from the prior year.
• Current Assets for Q1 2026 stood at $178.4 million, down from $198.7 million in the prior quarter.
• The five-year high for Current Assets was $448.5 million in Q2 2023, with the low at $178.4 million in Q1 2026.
• Historically, Current Assets has averaged $296.2 million across 5 years, with a median of $286.6 million in 2024.
• Annual changes were most pronounced in 2023 — Current Assets surged 43.26% — and 2024, when it sank 36.1%.
• Enanta Pharmaceuticals' Current Assets stood at $283.7 million in 2022, then soared by 37.57% to $390.3 million in 2023, then slumped by 31.3% to $268.1 million in 2024, then fell by 25.9% to $198.7 million in 2025, then declined by 10.2% to $178.4 million in 2026.
• The last three Current Assets figures came in at $178.4 million (Q1 2026), $198.7 million (Q4 2025), and $204.3 million (Q3 2025), per Business Quant data.